Deepinder Goyal's Temple wearable: apology to doctors, 'not a medical device'

Zomato founder Deepinder Goyal has apologised for addressing "all Indian doctors" in a social media post that defended Temple, the head-worn wearable his new company is selling, after medical professionals online questioned the device's claims. In a follow-up post on X on 6-7 November 2026, Goyal said he "should not have bucketed all Indian doctors into one single box" and that his anger was aimed at "a few influencer doctors". He has also said Temple is a wellness device, not a medical device. Early-access invitations list Temple at Rs 85,000.

Goyal is one of India's best-known founders. He built the food-delivery company Zomato and has said he stepped back from his chief executive role at its parent, Eternal, to work on Temple. When a founder of his profile launches a health-related gadget, the claims attract close attention, and the row shows how quickly doctors, users and the public now test such claims online.

The dispute is about what the device can actually measure. Cerebral blood flow means the flow of blood through the brain. Doctors on social media have questioned whether a sensor on the temple, the flat area at the side of the forehead, can give a reliable picture of blood flow inside the brain. Some also said Goyal's money and personal commitment do not answer questions about scientific accuracy. Goyal has acknowledged that the product's scientific validation is still developing, and he has described Temple as a fitness tracker and wellness device.

His first post also made a business argument. He said that if Temple were a scam, buyers would know within days of using it, and that the 14-day, no-questions-asked return policy protects them. His later apology narrowed his criticism to what he called influencer doctors, whom he accused of skipping Temple's research and distorting facts.

Peepals calculation: Of the roughly $30 million Goyal says has been spent on Temple, his own $20 million is about two-thirds (20 ÷ 30 = 67%). The $54 million friends-and-family round reported in February is about 1.8 times the amount spent so far (54 ÷ 30). Our calculation from the reported figures.

Short-term: The apology may calm the public argument, but early buyers and doctors will keep asking for published evidence on what the readings mean. Pre-order customers can use the return window if the device does not meet their expectations.

Long-term: Temple's credibility will depend on peer-reviewed research showing that its readings are accurate and useful. The case is also likely to feed the wider debate on how India regulates consumer health gadgets that sit between fitness trackers and medical devices.

Who is affected: Buyers considering an expensive wellness wearable; athletes and fitness users, whom the company targets; doctors asked by patients about such devices; and investors in India's health-technology start-ups.

Questions and Answers